Acrivon Therapeutics News

Ladenburg Thalmann Downgrades Acrivon Therapeutics to Neutral

Acrivon Therapeutics (ACRV) Price: 8.28, Change: -0.18, Percent Change: -2.13

MT NewswiresApr 29 07:08 ET

Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Acrivon Therapeutics, Inc. (ACRV)

TipRanksApr 27 08:10 ET

Acrivon Therapeutics Is Maintained at Outperform by BMO Capital

Acrivon Therapeutics Is Maintained at Outperform by BMO Capital

Dow JonesApr 26 14:12 ET

Express News | BMO Capital Maintains Outperform on Acrivon Therapeutics, Raises Price Target to $25

BenzingaApr 26 14:01 ET

Buy Rating on Acrivon Therapeutics With Increased Target Price Amid Promising ACR-368 Trial Data

TipRanksApr 26 07:20 ET

Express News | Acrivon Therapeutics Inc : BMO Raises Target Price to $25 From $18

ReutersApr 26 07:01 ET

Acrivon Therapeutics: Strong Buy on Impressive Clinical Outcomes and Market Potential

TipRanksApr 25 12:46 ET

Acrivon Therapeutics Is Maintained at Overweight by Piper Sandler

Acrivon Therapeutics Is Maintained at Overweight by Piper Sandler

Dow JonesApr 25 09:04 ET

Acrivon Therapeutics Price Target Raised to $30.00/Share From $26.00 by Piper Sandler

Acrivon Therapeutics Price Target Raised to $30.00/Share From $26.00 by Piper Sandler

Dow JonesApr 25 09:04 ET

Express News | Piper Sandler Maintains Overweight on Acrivon Therapeutics, Raises Price Target to $30

BenzingaApr 25 08:53 ET

Express News | HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $20 Price Target

BenzingaApr 25 07:29 ET

Acrivon Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/25/2024 85.87% HC Wainwright & Co. → $20 Reiterates Buy → Buy 04/05/2024 30.11% Ladenburg Thalmann $18

BenzingaApr 25 07:27 ET

Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Acrivon Therapeutics, Inc. (ACRV) and Gain Therapeutics (GANX)

TipRanksApr 25 06:30 ET

Acrivon Therapeutics (ACRV) Stock Surges: Unveiling Clinical Breakthroughs

Acrivon Therapeutics, Inc. (NASDAQ: ACRV) witnessed a notable ascent on the US stock exchanges following the close of trading yesterday. Acrivon's shares surged by 13.47% to reach $10.78 in the after-market session, countering a daytime dip of 3.26% that settled at $9.50. Investor confidence was bolstered after the company held an event to unveil encouraging ...

Stocks TelegraphApr 25 04:08 ET

Acrivon Therapeutics: Strong Buy Recommendation on Impressive AP3 Platform and ACR-368 Data Validation

TipRanksApr 25 00:45 ET

Express News | Acrivon Therapeutics Inc : Jefferies Raises Target Price to $18 From $12

Moomoo 24/7Apr 25 00:43 ET

Acrivon Therapeutics' Shares Climb 14% on Plans to Present Cancer Test Data

Shares of Acrivon Therapeutics advanced in post-market trading after the biopharmaceutical company said it would present clinical trial data in connection with a biomarker test for ovarian and endometrial cancers.

WSJApr 24 18:26 ET

Express News | Acrivon Therapeutics Shares Are Trading Higher After the Company Reported Initial Clinical Data for ACR-368 and Pipeline Program Progress Today at a Corporate R&D Event

Moomoo 24/7Apr 24 16:49 ET

Express News | Acrivon Therapeutics Reports A 50% Confirmed Overall Response Rate Observed With ACR-368 In Oncosignature-Positive Gynecological Cancers; Initial Clinical Validation Of AP3 Patient Selection Platform, Demonstrated Ability To Prospectively Predict ACR-368

Moomoo 24/7Apr 24 16:44 ET

Express News | Acrivon Therapeutics Inc - Preliminary Cash and Cash Equivalents and Short-Term Investments Balance of Approximately $110 Mln as of March 31, 2024

Moomoo 24/7Apr 24 16:36 ET